Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma
Authors:
Open Access
- 20 October 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0164554
Abstract
Recent studies have shown that intratumoral heterogeneity (ITH) is prevalent in clear cell renal cell carcinoma (ccRCC), based on DNA sequencing and chromosome aberration analysis of multiple regions from the same tumor. VHL mutations were found to be universal throughout individual tumors when it occurred (ubiquitous), while the mutations in other tumor suppressor genes tended to be detected only in parts of the tumors (subclonal). ITH has been studied mostly by DNA sequencing in limited numbers of samples, either by whole genome sequencing or by targeted sequencing. It is not known whether immunohistochemistry (IHC) can be used as a tool to study ITH. To address this question, we examined the protein expression of PBRM1, and PBRM1-related proteins such as ARID1A, SETD2, BRG1, and BRM. Altogether, 160 ccRCC (40 per stage) were used to generate a tissue microarray (TMA), with four foci from each tumor included. Loss of expression was defined as 0–5% of tumor cells with positive nuclear staining in an individual focus. We found that 49/160 (31%), 81/160 (51%), 23/160 (14%), 24/160 (15%), and 61/160 (38%) of ccRCC showed loss of expression of PBRM1, ARID1A, SETD2, BRG1, and BRM, respectively, and that IHC could successfully detect a high prevalence of ITH. Phylogenetic trees were constructed that reflected the ITH. Striking co-losses among proteins were also observed. For instance, ARID1A loss almost always accompanied PBRM1 loss, whereas BRM loss accompanied loss of BRG1, PBRM1 or ARID1A. SETD2 loss frequently occurred with loss of one or more of the other four proteins. Finally, in order to learn the impact of combined losses, we compared the tumor growth after cells acquired losses of ARID1A, PBRM1, or both in a xenograft model. The results suggest that ARID1A loss has a greater tumor-promoting effect than PBRM1 loss, indicating that xenograft analysis is a useful tool to investigate how these losses impact on tumor behavior, either alone or in combination.Keywords
Funding Information
- National Cancer Institute (5R01CA155015)
- National Cancer Institute (5P30CA056036-14)
- National Cancer Institute (5R01CA175691)
- National Cancer Institute (P30 CA06927)
This publication has 35 references indexed in Scilit:
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingNature Genetics, 2014
- Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profilingThe Journal of Pathology, 2013
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamicsProceedings of the National Academy of Sciences, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Tumour evolution inferred by single-cell sequencingNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Genetic variegation of clonal architecture and propagating cells in leukaemiaNature, 2010
- The patterns and dynamics of genomic instability in metastatic pancreatic cancerNature, 2010
- Clonality Assessment and Clonal Ordering of Individual Neoplastic Crypts Shows Polyclonality of Colorectal AdenomasGastroenterology, 2010
- Molecular basis of the VHL hereditary cancer syndromeNature Reviews Cancer, 2002